61.42
-0.01 (-0.02%)
| Previous Close | 61.43 |
| Volume | 5,206,690 |
| Avg. Volume (3M) | 2,216,528 |
| Market Cap | 11,896,730,624 |
| Price / Earnings (TTM) | 158.14 |
| Price / Earnings (Forward) | 9.31 |
| Price / Sales | 3.29 |
| Price / Book | 1.90 |
| 52 Weeks Range | |
| Earnings Date | 2 Nov 2026 |
| Profit Margin | -0.52% |
| Operating Margin (TTM) | 16.34% |
| Diluted EPS (TTM) | -0.100 |
| Quarterly Revenue Growth (YOY) | 32.00% |
| Quarterly Earnings Growth (YOY) | 109.40% |
| Total Debt/Equity (MRQ) | 66.98% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | 676.62 M |
| Levered Free Cash Flow (TTM) | -16.04 M |
| Return on Assets (TTM) | 3.89% |
| Return on Equity (TTM) | -0.31% |
News Mood
-
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
5 days ago, 7:12AM
-
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
11 Nov, 7:12PM
-
BioMarin (BMRN) Q3 2026 Earnings Call Transcript
02 Nov, 10:43PM
-
BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ...
03 Nov, 9:02PM
-
BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
03 Nov, 5:19AM
-
BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut
02 Nov, 8:09PM
AIStockmoo Score
| Value 30% | 0.0 |
| Cheaper than its usual valuation. Counted for less, as it made a loss in recent years. info | |
| Earns below its cost of capital. Returns on capital rising. info | |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Holdings' Value info | NA |
| Risk Premium info | NA |
| Market Valuation info | NA |
| Timing 30% | -0.1 |
| No clear trend over the past year. Somewhat below its 52-week high. info | |
| No clear trend: the price is moving around its moving averages. It is close to them. info | |
| From our AI technical analysis of the chart. info | NA |
| Candle Patterns info | NA |
| Sentiment 20% | 0.0 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mixed or neutral. info | |
| Holdings' Sentiment info | NA |
| Smart Money 20% | 0.2 |
| Institutions net +0.87% of shares in their latest 13F filings: 301 holders increased, 266 decreased (quarter to 30 Sep 2026). info | |
| Short interest +43.0% from 31 Aug to 30 Oct 2026, 5.8 days to cover (FINRA). info | |
| Insider Activity info | NA |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| No pillar has a clear reading, so the score is unchanged. | |
| Not in score | |
| Earnings per share have risen every year. Made a loss in recent years. info | |
| Near its medium-term trend line. info | |
| Price is high against its 52-week average. Down over 5 years. info | |
| Short-term momentum rising. info | |
| Price is near support. info | |
| Final Score | 0.02 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | BioMarin Pharmaceutical Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B | Score |
|---|---|---|---|---|---|
| BMRN | 12 B | - | 158.14 | 1.90 | 0.0 |
| ROIV | 28 B | - | - | 6.97 | 1.0 |
| INCY | 23 B | - | 58.48 | 4.26 | 0.7 |
| SYRE | 9 B | - | - | 10.08 | 1.1 |
| MDGL | 9 B | - | - | 14.74 | -0.4 |
| CORT | 7 B | - | 47.78 | 8.89 | -1.5 |
Select this tab to load the latest available analysis.
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.38% |
| % Held by Institutions | 103.99% |
No data within this time range.
No data within this time range.
Institutions
Institutional ownership: 110.75%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 301 | 20,250,655 |
| Decreased | 266 | 18,634,244 |
| New | 90 | 3,927,888 |
| Sold out | 77 | 3,856,889 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 14,122,815 | 5.8 |
| 15 Oct 2026 | 12,050,657 | 4.9 |
| 30 Sep 2026 | 11,522,835 | 5.5 |
| 15 Sep 2026 | 10,075,655 | 5.5 |
| 31 Aug 2026 | 9,877,553 | 5.8 |
| 14 Aug 2026 | 10,202,950 | 3.7 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 19 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical Bets on Amicus Growth as VOXZOGO Competition Concerns Mount
BioMarin Pharmaceutical (NASDAQ:BMRN) is betting that a growing rare-disease pipeline and its integration of Amicus will help sustain growth, as executives seek to address investor concerns about competition for its VOXZOGO treatment. The company expects revenue of $3.8 billion to $3.9 billion in 2… |
| 18 Nov 2026 | Yahoo Finance |
How Investors Are Reacting To BioMarin (BMRN) Acquired Drug Growth Prospects
BioMarin Pharmaceutical scheduled three investor conference appearances in November 2026 in New York and London, highlighting its rare-disease portfolio and development pipeline to a global healthcare audience. Management highlighted up to US$2.6b in peak annual sales potential from acquired Amicus… |
| 16 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
BioMarin Pharmaceutical (NASDAQ:BMRN) expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference. Hardy said the company’s global… |
| 11 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
BioMarin Pharmaceutical (NASDAQ:BMRN) is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion. Chief Financial Officer Brian Mueller said third-quarter revenue rose 32% to $1 bi… |
| 04 Nov 2026 | Yahoo Finance |
BioMarin to Participate in Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November. |
| 03 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical Inc (BMRN) Q3 2026 Earnings Call Highlights: First $1 Billion Revenue ...
BioMarin Pharmaceutical Inc (BMRN) topped $1 billion in quarterly revenue for the first time with 32% growth, but trimmed full-year 2026 guidance on order timing and Middle East disruption. |
| 03 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical Inc. Q3 2026 Earnings Call Summary
Moby summary of BioMarin Pharmaceutical Inc.'s Q3 2026 earnings call… |
| 03 Nov 2026 | Yahoo Finance |
BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported third-quarter revenue above Wall Street expectations, supported by stronger-than-anticipated sales across several treatments for rare diseases. |
| 02 Nov 2026 | Yahoo Finance |
BioMarin (BMRN) Q3 2026 Earnings Call Transcript
Revenue topped $1 billion for first time, fueled by Amicus integration. |
| 02 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic condit… |
| 02 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical (BMRN) Could Be 21% Undervalued On Mixed Q3 Guidance Cut
BioMarin Pharmaceutical (BMRN) is back in focus after a mixed Q3 2026 update, with adjusted profit topping analyst expectations while sales came in slightly below forecasts and full year guidance moved lower. Recent trading tells a mixed story for BioMarin Pharmaceutical. The share price slipped… |
| 02 Nov 2026 | Yahoo Finance |
BioMarin (BMRN) Stock May Be A Bargain After Fabry Therapy Deal
BioMarin Pharmaceutical has been busy, with a large acquisition, fresh Fabry disease assets and a stock price that is still down over the longer stretch, which naturally raises a question about how much investors are paying today for the company’s sales base. For anyone tracking rare disease drug… |
| 02 Nov 2026 | Yahoo Finance |
BioMarin: Q3 Earnings Snapshot
(AP) — BioMarin Pharmaceutical Inc. (BMRN) on Monday reported a loss of $122… |
| 02 Nov 2026 | Yahoo Finance |
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
| 02 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of +355.56% and -0.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 02 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical (NASDAQ:BMRN) reports Q3 2026 in line with expectations but full-year sales guidance misses expectations
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) met Wall Street’s revenue expectations in Q3 2026, with revenue up 32% year on year to $1.02 billion. On the other hand, the company’s full-year revenue guidance of $3.85 billion at the midpoint came in 1.8% below analysts’ consensus estimates.… |
| 02 Nov 2026 | Yahoo Finance |
BioMarin Reports Third Quarter 2026 Financial and Operating Results
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2026… |
| 01 Nov 2026 | Yahoo Finance |
BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be announcing earnings results tomorrow after market hours. Here’s what investors should know. |
| 30 Oct 2026 | Yahoo Finance |
Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking
U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. |
| 29 Oct 2026 | Yahoo Finance |
Exelixis (EXEL) vs. BMRN and NBIX: Can CABOMETYX and Pipeline Growth Revive Investor Confidence?
Is EXEL a good stock to buy? We came across a bullish thesis on Exelixis, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on EXEL. Exelixis, Inc.’s share was trading at $66.28 as of October 28th 2026. EXEL’s trailing and forward P/E were 20.62 and 15.25… |
| Show more | ||
Recent Signals candle patterns and EMA crosses
Technical Setup Medium
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |